On Monday, Indivior Pharmaceuticals (NASDAQ:INDV) went out on a positive note, in a manner of speaking. That's because the first trading session of November marked its last day as a stand-alone company and stock. On news of its successful merger with a partner, investors bid it farewell, sending its shares up more than 3% that day. That morning, Indivior announced that its merger with peer Supernus Pharmaceuticals (NASDAQ:SUPN) had closed. This creates, in Indivior's words, "a leading diversified, central nervous system (CNS) biopharmaceutical company." Image source: Getty Images.
CryptoAlerta — análise de criptomoedas e mercado em tempo real